Perspectives for delivery of therapeutics by extravasation of biodegradable microspheres in the brain  

作　　者：Anne-Eva van der Wijk Ed VanBavel 

机构地区：[1]Amsterdam UMC location University of Amsterdam,Department of Biomedical Engineering and Physics,Amsterdam,The Netherlands [2]Amsterdam Neuroscience,Neurovascular Disorders Program,Amsterdam,The Netherlands [3]Amsterdam Cardiovascular Sciences,Microcirculation Program,Amsterdam,The Netherlands

出　　处：《Neural Regeneration Research》2024年第5期969-970,共2页中国神经再生研究（英文版）

基　　金：supported by Amsterdam Neuroscience(project number NDIS-2019-03,to AEW and EVB).

摘　　要：Development of therapeutics for brain diseases has remained challenging,in particular due to the difficulty of passing the blood-brain barrier.As a result,the current arsenal of therapeutics targeting the brain is limited to small,lipid-soluble drugs and there is a lack of options for treating neuroblastomas,Alzheimer’s disease,and many other devastating pathologies.Despite the advances in strategies for crossing the blood-brain barrier such as the use of nanoparticles(Hersh et al.,2022;Duan et al.,2023),such delivery systems have not yet reached clinical practice.Therefore,novel platforms for the transport of therapeutics across the blood-brain barrier remain highly desired.This specifically holds for large molecules such as monoclonal antibodies and recombinant proteins,as well as nucleotide-based therapeutics and cell therapies.Research efforts in this field are increasing exponentially,with thousands of publications in the last few years.

关 键 词：THERAPEUTICS holds SPITE 

分 类 号：R741[医药卫生—神经病学与精神病学]